Skip to main content

Table 2 Baseline characteristics of participants enrolled in the 2017–2018 therapeutic efficacy study, Burkina Faso

From: Anti-malarial efficacy and resistance monitoring of artemether-lumefantrine and dihydroartemisinin-piperaquine shows inadequate efficacy in children in Burkina Faso, 2017–2018

  Niangoloko Nanoro Gourcy
AL DP AL DP AL DP
Screened 375 335 324
Included in analysis (%) 116 118 117 113 120 118
Age in months. mean (SD) 33.6 (13.2) 33.6 (13.2) 33.6 (13.2) 31.2 (12.0) 34.8 (12.0) 34.8 (12.0)
Sex (male) n (%) 58 (50) 68 (57.6) 57 (48.7) 61 (53.0) 59 (49.2) 62 (52.5)
Weight (kg). mean (SD) 12.0 (2.7) 12.1 (2.7) 11.6 (2.0) 11.2 (2.2) 11.8 (2.2) 11.7 (2.3)
Temperature in °C, mean (SD) 38.3 (1.0) 38.3 (1.0) 38.2 (1.1) 38.1 (1.1) 38.1 (1.2) 38.2 (1.0)
Parasitaemia day 0a 36,594 36,571 48,891 42,393 42,116 33,536
Hemoglobin in g/dl. mean (SD) 10.2 (1.7) 10.0 (2.9) 9.9 (1.7) 10.1 (1.6) 10.0 (1.5) 9.9 (1.6)
  1. AL artemether lumefantrine, DP dihydroartemisinin piperaquine, SD standard deviation
  2. ageometric mean parasite density (asexual parasites/µl)